|GRANTWAY
EN

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
13 March 2023
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
United States of America
Health, Justice and Social Welfare Research, Development and Innovation
Overview

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21) This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care, irrespective of participants ancestral origins or sociodemographic status. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
19 April 2023